厄贝沙坦氢氯噻嗪在感知R波抑制型起搏器患者中的应用观察

目的 观察厄贝沙坦氢氯噻嗪在心室起搏心室感知R波抑制型(VVI)起搏器患者中的应用.方法 入选91例患者随机分为观察组47例,对照组44例.观察组术后口服厄贝沙坦氢氯噻嗪75～150 mg/d;对照组未口服厄贝沙坦氢氯噻嗪.随访6个月均检测血浆脑利钠肤(BNP),并行彩色多普勒超声检查监测左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)和右心室内径(RVD),进行组内及组间比较.结果 观察组患者服药后6个月LVEDD、LVESD、RVD和BNP均比治疗前有明显降低,LVEDD(49.21±7.21)mm vs(46.75±8.05)mm,LVESD(30.31±7.26)mm vs(28.65±6.97)mm,RVD(20.57±L 23)mm vs(18.15±1.16)mm,BNP(232.4±23.36)ng/L vs(168.7±21.65)ng/L,LVEF有明显增高,LVEF(44.85±5.95)%vs(49.67±6.72)%(P＜0.05或＜0.01);对照组患者随访6个月后LVEDD、LVESD、RVD和BNP均比治疗前升高,LVEDD(50.12±7.52)mm vs(53.46±8.15)mm,LVESD(29.72±7.63)mm vs(32.69±8.05)mm,RVD(19.86±1.62)mm vs(20.25±1.87)mm,BNP(230.5±21.85)ng/L vs(250.6±25.65)ng/L,LVEF有明显降低,LVEF(45.25±6.35)%vs(42.35±4.95)%(P＜0.05),治疗后两组LVEDD、LVESD、LVEF、RVD和BNP差异均有统计学意义(P＜0.01).结论 VVI起搏器植入后常规应用厄贝沙坦氢氯噻嗪不失为一种简单、安全、有效的治疗方法,对患者病情及预后十分有益.

Application of irbesartan hydrochlorothiazide tablet in patients with ventricular sensing R wave inhibition cardiac pacemakers

Objective To observe the application of irbesartan hydrochlorothiazide tablet in VVI cardiac(ventricular pacing ventricular sensing R wave inhibition) pacemaker patients.Methods The patients were randomly divided into two groups,observation group 47 cases,control group 44 cases.The patients in observation group had oral administration of irbesartan hydrochlorothiazide 75-150 mg/d after operation;control group did not have oral irbesartan hydrochlorothiazide.Before pacemaker implantation and in 6 months afte...